NEKTAR THERAPEUTICS 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors: Jeff Ajer

NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Jeff Ajer”): 89,572,592 for, 5,310,752 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 23,712,753 for, 219,719 against.

Description as filed by funds: Election of Directors: Robert B. Chess

NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Robert B. Chess”): 87,385,092 for, 7,518,984 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 23,582,241 for, 350,231 against.

Description as filed by funds: Election of Directors: Roy A. Whitfield

NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Roy A. Whitfield”): 85,885,290 for, 8,993,582 against, per its Form 8-K filed June 6, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 22,931,243 for, 1,001,229 against.

Description as filed by funds: To approve an amendment to our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 8,000,000 shares.

NEKTAR THERAPEUTICS’s own tally for this item (“2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 8,000,000 shares”): 86,500,506 for, 7,507,037 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 8,000,000 shares was approved with the following votes.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 23 asset managers below reported 23,742,503 for, 220,419 against.

Description as filed by funds: To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).

NEKTAR THERAPEUTICS’s own tally for this item (“4. Proposal to approve the non-binding advisory resolution regarding our executive compensation”): 87,037,178 for, 6,730,748 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 20 managers: 23,932,472 for.

Institutional-manager reports, all 107 managers: 63,297,723 for, 1,126,881 against, 5,030,874 abstained, 10,000 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

NEKTAR THERAPEUTICS’s own tally for this item (“3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 139,098,119 for, 1,556,508 against — passed, per its Form 8-K filed June 6, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved with the following votes.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 20 asset managers below reported 23,932,472 for.